Luxturna (Voretigene neparvovec-rzyl) was the historic first in vivo AAV gene therapy approved by the U.S. FDA, indicated for inherited retinal dystrophies caused by biallelic mutations in the RPE65 gene. Delivered via a single micro-surgical subretinal injection of recombinant AAV2, Luxturna restores the isomerohydrolase enzyme essential for synthesizing 11-cis-retinal in the biochemical visual cycle, restoring functional vision and light sensitivity in patients facing childhood blindness.
For centuries, children born with severe inherited retinal dystrophies - such as Leber Congenital Amaurosis (LCA) and early-onset retinitis pigmentosa - faced an irreversible diagnosis: progressive loss of night vision in early childhood followed by complete blindness in young adulthood.
In 2017, the landscape of ophthalmology and genetic medicine was permanently altered with the FDA approval of Luxturna (Voretigene neparvovec-rzyl).
As the first approved in vivo viral vector gene therapy in the United States, Luxturna proved that delivering functional DNA into specialized sensory cells can directly restore lost human vision.
How does the RPE65 isomerohydrolase enzyme power the biochemical visual cycle, how is Luxturna delivered surgically into the subretinal space, and how do clinicians measure visual recovery?
The Root Cause: The Broken Biochemical Visual Cycle#
To understand how Luxturna works, examine how the human eye captures light:
[Incoming Photon of Light Hits Rhodopsin in Retina]
│
▼
[11-cis-retinal Is Converted to All-trans-retinal]
│ (Light Signal Sent to Brain via Optic Nerve)
▼
[All-trans-retinal Moves to Retinal Pigment Epithelium (RPE)]
│
▼
[RPE65 ENZYME IS MUTATED / NON-FUNCTIONAL]
│
▼
[Visual Cycle Halts ──► 11-cis-retinal CANNOT Be Regenerated]
│
▼
[Photoreceptors Starve of Chromophore ──► PROGRESSIVE BLINDNESS]
- The RPE65 Enzyme: In a healthy eye, the RPE65 gene encodes an all-trans retinyl ester isomerohydrolase located inside the retinal pigment epithelium.
- The Defect: When a child inherits two defective copies of the RPE65 gene (biallelic mutations), the enzyme is absent.
- The Clinical Outcome: Photoreceptors remain structurally present during childhood but cannot regenerate 11-cis-retinal. Patients suffer from profound nyctalopia (night blindness), tunnel vision, involuntary eye movements (nystagmus), and progressive retinal degeneration.
How Luxturna Works: The Subretinal AAV2 Repair#
Luxturna delivers a healthy copy of the human RPE65 cDNA directly to the target cells:
- The Vector: Utilizes a Recombinant Adeno-Associated Virus Serotype 2 (AAV2), which possesses natural, highly specific tropism for the human retinal pigment epithelium.
- The Surgical Delivery:
- A specialized vitreoretinal surgeon performs a pars plana vitrectomy to remove the vitreous gel of the eye.
- Using a microscopic 41-gauge cannula, the surgeon performs a subretinal micro-injection, placing $1.5 \times 10^$ vector genomes directly into the subretinal space between the RPE and the neurosensory retina.
- The fluid creates a localized, temporary retinal bleb that resolves within days as the AAV2 particles enter the RPE cells.
- The Cellular Cure: The functional RPE65 gene circularizes inside the RPE cell nuclei, synthesizing normal isomerohydrolase enzymes to restart the visual cycle permanently.
Measuring Clinical Efficacy: The Multi-Luminance Mobility Test#
To evaluate real-world visual recovery in clinical trials, researchers developed the Multi-Luminance Mobility Test (MLMT):
| Lighting Level (Lux) | Real-World Equivalent Lighting Condition | Pre-Treatment Baseline | Post-Luxturna Outcome |
|---|---|---|---|
| 400 Lux | Bright office interior or retail store. | Patient struggles or requires a cane. | Navigates easily and rapidly. |
| 50 Lux | Dimly lit restaurant or living room. | Cannot identify obstacles; fails test. | Passes independently. |
| 1 Lux | Outdoor sidewalk under a dim full moon. | Complete functional blindness. | Significant proportion of patients successfully navigate obstacles in near-total darkness. |
- Clinical Impact: Over 90% of clinical trial participants demonstrated meaningful improvements in functional navigation under dim lighting conditions within 30 days of treatment.
Diagnostic Confirmation: Who Is a Candidate?#
To qualify for Luxturna therapy, patients must satisfy two strict clinical criteria:
- Genetic Confirmation: Documented biallelic (homozygous or compound heterozygous) pathogenic mutations in the RPE65 gene confirmed via certified next-generation genetic sequencing.
- Viable Retinal Cells: Sufficient remaining viable retinal tissue, confirmed by optical coherence tomography (OCT) showing an intact outer nuclear layer and ≥ 3 disc areas of retina without atrophy.
Because the interior of the eye is an immune-privileged compartment, subretinal AAV2 delivery requires a fraction of the vector dose used in systemic therapies ($1.5 \times 10^$ vs $10^$ vg), minimizing systemic immune activation.
To explore the foundations of viral vectors and in vivo delivery, read What Is Gene Therapy? In Vivo vs. Ex Vivo Delivery Explained.
Track Your Health & Genomic Biomarkers with Meridian#
Monitoring your laboratory blood biomarkers over time gives you objective validation that your cellular health, liver enzymes, and hematologic profiles remain in optimal ranges.
Meridian is an offline personal health vault for iPhone designed to give you complete ownership of your medical diagnostic data.
- Instant Lab Report Extraction: Take a photo or upload a PDF of your Complete Blood Count, Comprehensive Metabolic Panel, and specialized genetic testing panels from Quest, Labcorp, or your clinic. Meridian extracts your biomarkers on-device using Apple VisionKit.
- Longitudinal Hematology Trends: Track your red blood cell indices, hemoglobin fractions, and liver enzymes with total privacy.
- 100% On-Device & Private: Protected by hardware AES-256 encryption and FaceID. Zero cloud servers. Zero data tracking.
Take control of your diagnostic medical records and privacy today. Download Meridian on the App Store and keep your health data organized, private, and secure.